Zobrazeno 1 - 10
of 20
pro vyhledávání: ''
Autor:
Xue Bai, Zhong-Yi Dong, Xin-Ran Tang, Si-Cong Ma, Hong-Bo Zhu, Dehua Wu, Jian-Guo Zhou, Zhi-Jiao Duan, Jian Wang, Li-Li Long, Xue-Jun Guo, Yan-Pei Zhang, Ze-Qin Guo, Qiang John Fu
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Objectives: Clinical benefits of immune-checkpoint blockade (ICB) versus standard chemotherapy have been established in unselected non-small cell lung cancer (NSCLC). However, the response to ICB therapy among patients is heterogeneous in clinical pr
Autor:
Karama Asleh, Elisabeth Specht Stovgaard, Torsten O. Nielsen, Samuel Leung, Nazia Riaz, Eva Balslev, Maj-Britt Jensen, Lise B. Nielsen, Dongxia Gao, Dorte Nielsen, Anne Vibeke Lænkholm
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
Stovgaard, E S, Asleh, K, Riaz, N, Leung, S, Gao, D, Nielsen, L B, Lænkholm, A V, Balslev, E, Jensen, M B, Nielsen, D & O Nielsen, T 2021, ' The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine ', OncoImmunology, vol. 10, no. 1, 1924492 . https://doi.org/10.1080/2162402X.2021.1924492
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
Stovgaard, E S, Asleh, K, Riaz, N, Leung, S, Gao, D, Nielsen, L B, Lænkholm, A V, Balslev, E, Jensen, M B, Nielsen, D & O Nielsen, T 2021, ' The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine ', OncoImmunology, vol. 10, no. 1, 1924492 . https://doi.org/10.1080/2162402X.2021.1924492
OncoImmunology, Vol 10, Iss 1 (2021)
Preclinical studies suggest that some effects of conventional chemotherapy, and in particular, gemcitabine, are mediated through enhanced antitumor immune responses. The objective of this study was to use material from a randomized clinical trial to
Publikováno v:
Oncoimmunology
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, Vol 9, Iss 1 (2020)
Although several biomarkers have been proposed to predict the response of patients with lung adenocarcinoma (LUAD) to immune checkpoint blockade (ICB) therapy, existing challenges such as test platform uniformity, cutoff value definition, and low fre
Autor:
Bernard Asselain, Guido Kroemer, Enora Laas, Laure-Sophie Talagrand, Lisa Derosa, Elisabetta Marangoni, Maël Priour, Marick Laé, Paule Opolon, Alice Pinheiro, Fabien Reyal, Laurence Zitvogel, Anne-Sophie Hamy, Diane De Croze, Jean-Yves Pierga, Beatriz Grandal, Lauren Darrigues, Julien Guerin, Satoru Yonekura, Constance Valdelièvre, Elodie Montaudon
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Oncoimmunology
Oncoimmunology
Immunosurveillance plays an important role in breast cancer (BC) prognosis and progression, and can be geared by immunogenic chemotherapy. In a cohort of 1023 BC patients treated with neoadjuvant chemotherapy (NAC), 40% of the individuals took comedi
Autor:
Rosina Paterra, Francesco DiMeco, Eugenio Parati, Laura Fariselli, Francesco Acerbi, Marica Eoli, Paolo Ferroli, Gaetano Finocchiaro, Bianca Pollo, Maria Grazia Bruzzone, Simona Frigerio, Carlo Antozzi, Cristina Corbetta, Valeria Cuccarini, Maura Servida, Sara Pessina, Stefania Cuzzubbo, Serena Pellegatta, Lucia Cuppini, Elena Anghileri
Publikováno v:
OncoImmunology, Vol 7, Iss 4 (2018)
In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal inj
Autor:
Florian Bochen, Armand Koch, Bernhard Schick, Sandrina Körner, Maximilian Linxweiler, Jan Philipp Kühn, Basel Al Kadah, Benedikt Balensiefer, Georgios Papaspyrou, Anke Marx, Frank Neumann, Jörg Thomas Bittenbring, Klaus Bumm, David Zuschlag, Silke Wemmert
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
Vitamin D deficiency is frequently observed in human cancer patients and a prognostic relevance could be shown for some entities. Additionally, it is known that vitamin D can stimulate the patients' antitumor immunity. However, valid epidemiological
Autor:
Ester Simeone, Antonio M. Grimaldi, Martina Strudel, Vito Vanella, Lucia Festino, Paolo A. Ascierto
Publikováno v:
OncoImmunology, Vol 7, Iss 1 (2018)
Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed
Autor:
Dai Liu, Don C. Rockey, E. Ramsay Camp, Guangfu Li, Todd D. Schell, Diego M. Avella, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Jussuf T. Kaifi, Mark P. Rubinstein
Publikováno v:
OncoImmunology, Vol 7, Iss 1 (2018)
Successful development of immunotherapeutic strategies for hepatocellular cancer (HCC) has been impeded by limited understanding of tumor-induced profound tolerance and lack of a clinically faithful HCC model. Recently, we developed a novel model tha
Autor:
Dan Ou, Julien Adam, Ingrid Garberis, Pierre Blanchard, France Nguyen, Antonin Levy, Odile Casiraghi, Philippe Gorphe, Ingrid Breuskin, François Janot, Stephane Temam, Jean-Yves Scoazec, Eric Deutsch, Yungan Tao
Publikováno v:
OncoImmunology, Vol 6, Iss 9 (2017)
To investigate the prognostic value of tumor infiltrating lymphocytes (TILs: CD8+ and FoxP3+), and PD-L1 expression in patients with head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy combined with cisplatin (CRT) or cetuximab (B
Autor:
Josephine Kang, Lorenzo Galluzzi
Publikováno v:
OncoImmunology, Vol 6, Iss 7 (2017)
In May 2017, the US Food and Drug Administration (FDA) granted accelerated approval to durvalumab (IMFINZI®, from AstraZeneca UK Limited) and avelumab (BAVENCIO®, EMD Serono, Inc.) for use in patie...